SBIR/STTR Research Award
SBIR Phase I: A new vaccine technology to engineer a potent and polarized immunity against COVID-19
Award amount
$255,998Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- Tempo Therapeutics Inc
- Proposal award date
- 2020-09-01
- Contract end date
- 2021-04-30
- UEI
- EA4HW67GFBS1
- Solicitation number
- Not reported
- Topic code
- PT
Research abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project will advance a new vaccine delivery technology against new emerging pathogens such as that causing COVID-19. This project will develop a new process that can be rapidly
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- STTR Phase II:VaxMAP a single dose multivalent vaccine to produce durable and cross-reactive immunity against various coronaviruses
- A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients
- MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds
- A flowable microporous biomaterial as a low cost, high efficacy diabetic chronic ulcer treatment
Research funding history
5 SBIR/STTR records share this UEI (2016–2023). Reported award amounts total $5,629,145. Reported amounts are not federal obligations.
Phases: Phase II – Direct to Phase II, Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation